NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA

OBJECTIVE: Refractory symptomatic plexiform neurofibromas (PNF) and inoperable refractory low grade gliomas (LGG) pose a clinical challenge that may be life threatening. Phase 1 and 2 clinical trials of MEK inhibition with selumetinib in inoperable PNF and LGG have demonstrated promising results in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Hounjet, Celine D, Ronsley, Rebecca, Cheng, Sylvia, Rassekh, S Rod, Duncan, Walter J, Dunham, Christopher, Gardiner, Jane, Ghag, Arvindera, P, Ludemann, Jeffrey, Wensley, David, Rehmus, Wingfield, Sargent, Michael A, Evans, Naomi, Popovska, Vesna, Hukin, Juliette
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Neurofibromatosis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715867/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.615
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires